Company(ies): AEterna Zentaris, Keryx Biopharmaceuticals
Principal Therapy Area: Cancer
£195 / $340 / €245
Perifosine is an alkylphospholipid compound that acts as a signal transduction inhibitor. The drug has a structure that is very similar to membrane phospholipids, therefore it is able to modify membrane-related signalling events. The signalling pathways that perifosine modulates include the Akt, MAPK and JNK pathways, which are associated with cell proliferation and apoptosis. As perifosine primarily interferes with proliferating cells, cancer cells are more sensitive to the action of perifosine. In addition, having an effect on the SAPK/JNK pathway, perifosine has the potential to enhance radiation-induced apoptosis.
Drugs that exert their effect on the Akt protein are of particular interest, since there is a high level of the activated form of this protein in tumours that are resistant to other forms of cancer therapy. Inhibiting the Akt protein could potentially overcome this resistance.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focussing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for email@example.com